GLP-1 receptor agonists
Also known as: GLP-1 RA, glucagon-like peptide-1, incretin-based therapy
GLP-1 receptor agonists in cardiometabolic and obesity research, including cardiovascular outcome trials and mechanistic studies.
What does the research say about GLP-1 receptor agonists?
The GLP-1 class spans semaglutide, liraglutide, and dual incretin agents. Synapse aggregates trials, outcomes studies, and mechanistic papers tagged to GLP-1 pharmacology and related MeSH concepts.
Synapse surfaces peer-reviewed research and researcher networks for informational purposes only. This page does not provide medical advice, dosing guidance, or treatment recommendations.
Research feed: GLP-1 receptor agonists
11 indexed papers matched to curated MeSH concepts in the last 90 days.
GLP-1 Receptor Agonists
Controlled trials show GLP-1 receptor agonists reduce cardiovascular risk and improve metabolic outcomes in diabetes and obesity, indicating broader therapeutic applications.
Patient Experiences With GLP-1 Receptor Agonists
Qualitative study explores patient experiences with GLP-1 receptor agonists, highlighting benefits, challenges, and support needs.
GLP-1 receptor agonists
Review explores GLP-1 receptor agonists' benefits and challenges for nurse practitioners, highlighting prescription considerations.
GLP-1 Receptor Agonists and Noncardiometabolic Outcomes
This umbrella review examines noncardiometabolic outcomes of GLP-1 receptor agonists, suggesting implications for safety and health associations.
GLP-1 Receptor Agonists and the Risk of Cholelithiasis: A Literature Review
Literature review examines gallstone risks in obese populations treated with GLP-1 receptor agonists, suggesting implications for patient management.
A Case of GLP-1 Receptor Agonist-Induced Lithium Neurotoxicity
The report describes a case of GLP-1 RA-induced lithium neurotoxicity, suggesting a need for enhanced surveillance when coadministering these medications.
Requires close lithium monitoring with GLP-1 RA initiation or switches in bipolar patients; leaves open interaction mechanisms pending pharmacokinetic studies.**[[1]](https://www.researchgate.
What obgyns need to know about GLP-1 receptor agonists
Review highlights safety and efficacy of GLP-1 receptor agonists in women's health, particularly in PCOS and pregnancy.
The Effect of GLP-1 Receptor Agonists on Epilepsy: No Appetite for Seizures
GLP-1 RAs linked to ~16% lower incident epilepsy risk in T2D vs other therapies.
May warrant GLP-1 RA preference in type 2 diabetes at epilepsy risk; leaves open causality pending randomized trials.
Survival and Recurrence With GLP-1 Receptor Agonists in Breast Cancer
Retrospective cohort study evaluates GLP-1 RA effects on survival in breast cancer, indicating potential benefits.
GLP-1 Receptor Agonists and Clinical Periodontal Outcomes: A Scoping Review
Scoping review maps clinical oral and periodontal outcomes in humans receiving GLP-1 receptor agonists, suggesting important implications for oral health.
Researchers studying GLP-1 receptor agonists
Researcher network data is loading or unavailable for this topic.
Follow GLP-1 receptor agonists literature with AI-enriched clinical evidence on Synapse.
Search GLP-1 receptor agonists on SynapsePowered by Synapse — AI-enriched analysis of 600,000+ peer-reviewed papers